In fact, in cells treated with a combination of bortezomib and HCQ there was a strong reduction in p62 levels compared with cells treated with HCQ alone, from 0.76 ± 0.05 to 0.41 ± 0.07 (p = 0.0003) in RPMI 8226 cells, from 1.29 ± 0.12 to 0.84 ± 0.07 (p = 0.001) in JJN-3 cells (Figure 2C,F), and from 1.45 ± 0.18 to 0.81 ± 0.36 in primary MM PCs (p = 0.0286) (Figure 3C,D). This evidence concerns the gene SQSTM1 and Miyoshi myopathy.